The Board of Directors entered into Amendment No. 1 to the Rights Agreement dated October 27, 2025, extending the Final Expiration Date of the company's shareholder rights plan (poison pill) until close of business on October 27, 2027. The amendment modifies the duration of the defensive measure but does not alter other terms of the original agreement. Neuphoria Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.
